Irrus Investments

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

FeelTect is a medical device company based in Galway, Ireland, founded in 2019. The company specializes in developing connected-health technology, specifically a pressure sensing device known as Tight Alright. This device is designed to measure and monitor sub-bandage pressure during compression therapy, which is crucial for treating venous leg ulcers (VLUs). Effective compression is essential; if the pressure is too loose, it fails to provide therapeutic benefits, while excessive pressure can pose serious risks. FeelTect's technology enables users to view live readings and recorded data, facilitating optimal and individualized treatment regimens. By improving the application and maintenance of safe sub-bandage pressure, FeelTect aims to enhance patient outcomes and reduce the associated health-economic burden.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovation aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant global market given the high prevalence of diabetic foot ulcers.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovation aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant global market given the high prevalence of diabetic foot ulcers.

Using the latest in-house technology Allview Healthcare gives you access to leading Consultant and surgical services Rapid diagnosis and care. Currently the largest dermatology provider across Ireland, servicing both the HSE (State Health Provider) and the VHI (Ireland's largest private insurance company) A highly experienced management team and board of directors with both medical and technical professionals whose main aim is to ensure that patients receive the best care by the best consultant at the right time. We work hard to ensure our best practice, clinical governance and quality assurance is at its highest level thus leading to extremely high patient satisfaction.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

OncoMark Limited, founded in 2007 and based in Dublin, Ireland, specializes in the discovery and development of diagnostics and therapeutic targets for cancer patients. As a spin-out from University College Dublin, the company focuses on creating companion diagnostic tests that enhance patient stratification in cancer drug development. These tests aid pharmaceutical companies in identifying patients for whom specific drugs are most likely to be effective, thereby improving clinical trial efficiency and success rates. OncoMark's portfolio includes tissue-based biomarker assays and a Biomarker Interpretation Workflow platform that automates various analyses, such as survival assessments and interpretation of immunohistochemistry staining. The company's diagnostic tests cover major cancer types, including breast, colorectal, prostate, and melanoma, and are supported by significant EU research and development funding. Led by CEO Dr. Mairin Rafferty, OncoMark is committed to improving treatment outcomes and quality of life for cancer patients.

Adama Innovations Ltd. is a company based in Dublin, Ireland, focused on developing nanotechnology solutions for advanced manufacturing. Established in 2010 as a spin-out from the CRANN nanotechnology institute at Trinity College Dublin, Adama Innovations specializes in creating high-resolution nanoscale probes fabricated from diamond. These probes are designed for use in atomic force microscopy, enabling precise imaging, measurement, and manipulation at the nanoscale. The company’s innovative technology allows for the creation of micro-patterns on ultra-hard materials, which can be applied in various industries, including medical device fabrication, labeling, and anti-counterfeiting. Additionally, Adama Innovations offers a range of products, including diamond sharp cones and flare-shaped probes, to enhance capabilities in metrology and precision engineering.

Embo Medical, located at the National University of Ireland, is focused on developing innovative medical devices for vascular embolization. The company is creating the Caterpillar, a groundbreaking one-shot embolization device designed to enhance the efficiency and safety of peripheral vascular embolization procedures. This device aims to significantly reduce procedural times, enabling physicians to perform embolizations in a more cost-effective manner. With approximately 180,000 such procedures conducted annually worldwide, Embo Medical is positioned to make a meaningful impact in the medical field by improving patient outcomes and streamlining medical practices.